Biktarvy for the treatment of HIV infection: Progress and prospects
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biktarvy for the treatment of HIV infection: Progress and prospects
Authors
Keywords
-
Journal
BIOCHEMICAL PHARMACOLOGY
Volume 217, Issue -, Pages 115862
Publisher
Elsevier BV
Online
2023-10-17
DOI
10.1016/j.bcp.2023.115862
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
- (2023) Anchalee Avihingsanon et al. Lancet HIV
- Safety and Tolerability of Once Daily Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Post-Exposure Prophylaxis after Sexual Exposure
- (2022) Kenneth H. Mayer et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Engineered human blood–brain barrier microfluidic model for vascular permeability analyses
- (2022) Cynthia Hajal et al. Nature Protocols
- Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
- (2022) Vicente Estrada et al. Pharmacoeconomics-Open
- Treatment initiation or switch to BIC/FTC/TAF – real-world safety and efficacy data from two HIV centers in Romania
- (2022) Oana Săndulescu et al. GERMS
- Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021
- (2022) Lene Ryom et al. HIV MEDICINE
- Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
- (2022) Anna Turkova et al. Lancet HIV
- A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
- (2022) Alexa Vyain Zhao et al. Retrovirology
- Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation
- (2022) Mao-Song Tsai et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2022) Rajesh T. Gandhi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review
- (2022) Claire L. Townsend et al. Journal of the International AIDS Society
- Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes
- (2021) Kirsten L. White et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A new combination bictegravir+tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 PrEP: A concept evaluation study.
- (2021) Subhra Mandal et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis
- (2021) Katharina Nickel et al. BMC INFECTIOUS DISEASES
- Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges
- (2021) Weisen Zhang et al. Advanced Science
- Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
- (2021) Franco Maggiolo et al. Infectious Diseases and Therapy
- Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review
- (2021) Sheldon D. Fields et al. Infectious Diseases and Therapy
- Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants
- (2021) Rima K Acosta et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV
- (2021) Jordan E. Lake et al. Current Opinion in HIV and AIDS
- Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
- (2021) Alexa B. D'Angelo et al. AIDS PATIENT CARE AND STDS
- Pharmacokinetics of bictegravir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV
- (2021) Engie Salama et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV
- (2021) Chloe Orkin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
- (2021) Debbie Hagins et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment
- (2021) Thibaut Gelé et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial
- (2021) Aditya H Gaur et al. Lancet Child & Adolescent Health
- Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir
- (2021) Leonardo Calza et al. AIDS
- Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States
- (2021) Bruno Emond et al. CURRENT MEDICAL RESEARCH AND OPINION
- Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre
- (2021) Juan Ambrosioni et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
- (2021) Charlotte-Paige Rolle et al. MEDICINE
- Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
- (2021) Bo‐Huang Liou et al. Journal of the International AIDS Society
- Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
- (2021) Hui-Min Chang et al. Infection and Drug Resistance
- Approved HIV reverse transcriptase inhibitors in the past decade
- (2021) Guangdi Li et al. Acta Pharmaceutica Sinica B
- Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort
- (2021) Alessandro Lazzaro et al. Diagnostics
- The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single‐tablet regimen in the expanding spectrum of fixed‐dose combination therapy for HIV
- (2020) H‐J Stellbrink et al. HIV MEDICINE
- Structural basis for strand-transfer inhibitor binding to HIV intasomes
- (2020) Dario Oliveira Passos et al. SCIENCE
- Structural basis of second-generation HIV integrase inhibitor action and viral resistance
- (2020) Nicola J. Cook et al. SCIENCE
- An Elvitegravir Nanoformulation Crosses the Blood–Brain Barrier and Suppresses HIV-1 Replication in Microglia
- (2020) Yuqing Gong et al. Viruses-Basel
- HIV-1 Integrase Inhibitors that are active against Drug-Resistant Integrase Mutants
- (2020) Steven J. Smith et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV
- (2020) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Close‐up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms
- (2020) Alan N. Engelman et al. FEBS Journal
- Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance
- (2020) Rima K. Acosta et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
- (2020) Chloe Orkin et al. Lancet HIV
- HIV and antiretroviral therapy-related fat alterations
- (2020) John R. Koethe et al. Nature Reviews Disease Primers
- Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)
- (2020) Arkaitz Imaz et al. CLINICAL INFECTIOUS DISEASES
- HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
- (2020) Kimberly K. Scarsi et al. DRUGS
- Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection
- (2020) Elena Bekerman et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments
- (2020) Simone Perazzolo et al. Frontiers in Pharmacology
- Comparison of the Antiviral Activity of Bictegravir Against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants
- (2019) Robert A. Smith et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study
- (2019) Subhra Mandal et al. ANTIVIRAL RESEARCH
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) Hans-Jürgen Stellbrink et al. Lancet HIV
- Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) David A Wohl et al. Lancet HIV
- Management of active tuberculosis in adults with HIV
- (2019) Graeme Meintjes et al. Lancet HIV
- Weight Gain Associated with Integrase Stand Transfer Inhibitor Use in Women
- (2019) Anne Marie Kerchberger et al. CLINICAL INFECTIOUS DISEASES
- Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
- (2019) Kristen Andreatta et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Erratum to: Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
- (2019) Kristen Andreatta et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals
- (2019) Nicolas A. Margot et al. JOURNAL OF MEDICAL VIROLOGY
- Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations
- (2019) Francesco Saladini et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women
- (2019) Cissy Kityo et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Global Burden of Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Systematic Review and Meta-analysis
- (2019) Steve Leumi et al. CLINICAL INFECTIOUS DISEASES
- Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
- (2018) Jean-Michel Molina et al. Lancet HIV
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
- (2018) Eric S Daar et al. Lancet HIV
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2017) Paul E Sax et al. LANCET
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
- (2017) Joel Gallant et al. LANCET
- Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
- (2017) Paul E Sax et al. Lancet HIV
- Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins
- (2014) Mario Regazzi et al. CLINICAL PHARMACOKINETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now